Boskabady Mohammad Hossein, Kaveh Mahsa, Shakeri Kaveh, Mohammadian Roshan Nama, Rezaee Ramin
Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Iran J Pharm Res. 2019 Fall;18(4):1947-1958. doi: 10.22037/ijpr.2019.13712.11817.
The effects of ( ; PO) on total and differential WBC count, and oxidant/antioxidant biomarkers in bronchoalveolar lavage fluid (BALF) as well as on lung pathology in asthmatic rats were examined. Rats were randomly divided into; control group (C), asthma group, asthma groups treated with either (rats that received PO 1, 2 and 4 mg/mL) or dexamethasone 1.25 μg/mL (D), (n = 8 in each group). Total and differential white blood cells (WBC) count, nitrite (NO), nitrate (NO), malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT) and thiol levels in rats BALF were evaluated and lung pathological features were studied. Total WBC count, eosinophil, neutrophil and monocyte percentages, levels of NO, NO, MDA in the BALF and most pathological scores in the lung were increased but lymphocyte percentage, SOD, CAT and thiol levels were decreased in the BALF of asthmatic animals ( < 0.05 to < 0.001). Treatment with significantly reduced total WBC, neutrophil, eosinophil, monocyte, NO, and NO, MDA, interstitial fibrosis, emphysema, interstitial inflammation and epithelial damage, but increased lymphocyte, SOD, CAT and thiol levels compared to asthma group ( < 0.05 to < 0.001). Dexamethasone-treated rats also showed significant improvements in most parameters compared to asthma group ( < 0.05 to < 0.001). Our results demonstrated the ameliorative effects of on total and differential WBC count and oxidant-antioxidant biomarkers levels in BALF as well as lung pathological features in asthmatic rats, which propose the usage of this extract as a preventive anti-inflammatory treatment against asthma.
研究了(;PO)对支气管肺泡灌洗液(BALF)中白细胞总数及分类计数、氧化/抗氧化生物标志物的影响,以及对哮喘大鼠肺部病理的影响。将大鼠随机分为;对照组(C)、哮喘组、用(接受PO 1、2和4 mg/mL的大鼠)或地塞米松1.25 μg/mL(D)治疗的哮喘组,(每组n = 8)。评估大鼠BALF中的白细胞总数及分类计数、亚硝酸盐(NO)、硝酸盐(NO)、丙二醛(MDA)、超氧化物歧化酶(SOD)、过氧化氢酶(CAT)和巯基水平,并研究肺部病理特征。哮喘动物BALF中的白细胞总数、嗜酸性粒细胞、中性粒细胞和单核细胞百分比、NO、NO、MDA水平以及肺部的大多数病理评分均升高,但淋巴细胞百分比、SOD、CAT和巯基水平降低(<0.05至<0.001)。与哮喘组相比,治疗显著降低了白细胞总数、中性粒细胞、嗜酸性粒细胞、单核细胞、NO和NO、MDA、间质纤维化、肺气肿、间质炎症和上皮损伤,但增加了淋巴细胞、SOD、CAT和巯基水平(<0.05至<0.001)。与哮喘组相比,地塞米松治疗的大鼠在大多数参数上也有显著改善(<0.05至<0.001)。我们的结果证明了对哮喘大鼠BALF中白细胞总数及分类计数和氧化-抗氧化生物标志物水平以及肺部病理特征具有改善作用,这表明该提取物可作为预防哮喘的抗炎治疗药物。